Disclosures. Overview of Workshop. Objectives. Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression
|
|
- Meredith McKinney
- 5 years ago
- Views:
Transcription
1 Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression Disclosures The speakers have no disclosures. Lisa Ochoa-Frongia, MD Christina Mangurian, MD, MAS L. Elizabeth Goldman, MD, MCR Margo Pumar, MD Overview of Workshop Objectives Review challenges in underserved populations Split into small groups to discuss cases Groups come together to review cases Audience questions Conclusions Objectives Understand challenges in diagnosing and treating anxiety and depression in underserved and vulnerable populations Review best practices Learn how to differentiate between different anxiety disorders Review management of treatment refractory depression 1
2 What best describes your training? Challenges in Underserved and Vulnerable Populations A. Resident B. Nurse Practitioner C. Physician s Assistant D. General Internist or Family Practitioner E. Psychiatrist F. Allied Health Professional 3% 62% 29% 3% R e s i d e n t N u r s e P r a c t i t i o n e r P h y s i c i a n s A s s i s t a n t G e n e r a l I n t e r n i s t o r F a m... 3% 0% P s y c h i a t r i s t A l l i e d H e a l t h P r o f e s s i o n a l Homelessness Poverty Food insecurity Language barriers Violence/crime Medical complexity Contributors to anxiety, depression Health disparities Immigrants Unemploymen t Trauma history Uninsured Standard treatment PLUS services Case 1: Mr. M ID/CC: 32 year-old Spanish-speaking man presenting to primary care with anxiety. HPI: Patient reports significant anxiety. At times so distressed by his symptoms that he thinks he might be better off dead. Numerous recent visits to the ER for chest pain, anxiety, negative cardiac workup. Recent heavy alcohol use and some recreational cocaine use in past. PMH: GERD Case 1: Mr. M Medications: Started paroxetine 20 mg two weeks ago, but does not want to continue since making him sleepy during day, not helping anxiety. Family history: father w/ anxiety, depression. No history of suicide attempts in family. Social history: Moved from Mexico 2 years ago, lives with father. Works in construction. 2
3 Case 1: Questions What is your behavioral differential diagnosis for Mr. M s anxiety? What instruments, testing, or additional questions could help you clarify his diagnosis? Case 1: Questions After being given additional information by your facilitator, what are your treatment recommendations for Mr. M? How would your treatment differ if he had a history of trauma? Are you concerned about suicide risk? How do you assess this? Anti depressants and Sedation Different patients have different responses Paroxetine generally most sedating SSRI Mirtazapine, Trazodone also very sedating, often used for insomnia Citalopram, escitalopram less sedating/neutral Fluoxetine more activating SNRIs (venlafaxine), bupropion more activating Suicide Risk Assessment Patients who died by suicide were over twice as likely to have PCP visit in month preceding death compared to psychiatrist (45% vs 20%) SAFE-T: Suicide Assessment Five-step Evaluation and Triage 3
4 Suicide Risk Assessment: SAFE T Case 1 Teaching Points Prior to initiating SSRI/SNRI, screen for symptoms/episodes of mania, trauma history Consider sedating vs. activating SSRI/SNRI Assess suicide risk in patients with SI SSRIS for anxiety: start low and go slow Adjunctive medications to bridge patient to SSRI effect: propranolol, hydroxyzine, BZDs Case 1 Teaching Points Continued Titrate to maximum SSRI dose as tolerated/until symptoms remit Track patient symptoms with a validated tool Switch to a different SSRI if no response to first at maximal dose by 6-8 weeks Case 2: Mrs. D ID/CC: 70 year-old woman with depression, MMP. Mrs. D s depression worsening, very low motivation. Has gained 9 pounds since last visit and back pain worsening. PHQ-9 score is 20. Stopped seeing therapist. PMH: CAD, DM-2, HTN, obesity and chronic low back pain w/sciatica. Treat minimum 6-8 months after sx remit When stopping anti-depressants, taper 4
5 Case 2: Mrs. D Medications: sertraline 200mg, aspirin, benazepril, carvedilol, atorvastatin, metformin, glipizide, gabapentin, acetaminophen Previously on citalopram for 3 years, stopped working, switched to escitalopram which failed, now on sertraline x 1 year. Case 2: Questions What is the most likely diagnosis of Mrs. D? Why? What would you do to treat her? Why? If you decide to cross-taper her to venlafaxine, how would you do this? Social history: widowed, lives alone, facing eviction Case 2 Teaching Points Definition of treatment-resistant depression: MDD not responding to at least two appropriate courses of antidepressants Algorithm for treatment-resistant depression: STAR-D If PCP comfortable with treating resistant depression, follow algorithm, otherwise refer Simplified STAR*D Algorithm for Treatment of Depression SSRI SNRI Bupropion Step 1 Switch OR Cont. and Augment: Buspar, Bupropion, CBT Switch to Mirtazapine, TCA OR Augment: SGA (Abilify, Seroquel), T3, Lithium, Stimulant Based on STAR D, Each of these with an 8 week trial at an adequate/tolerated dose. Bupropion, venlafaxine should be prescribed in sustained/extended release. 5
6 Case 2 Teaching Points Continued Be aware of other conditions: choose medications that might kill two birds with one stone. Depression or anxiety with chronic pain: TCAs, SNRIs Gabapentin and pregabalin also w/anxiolytic effects Anxiety + psychosis: quetiapine has some evidence for off-label use Depression or anxiety with insomnia: mirtazapine When To Refer to Psychiatry When diagnosis is not clear Serious mental illness Depression with psychotic features When medications indicated are beyond PCP s scope of practice (mood stabilizers, antipsychotics) Summary: Advanced Cases in Anxiety and Depression Importance of screening patients for anxiety, depression, using validated tools Keep in mind evidence-based algorithms Follow best practices in medication prescribing Advocate for increased integration of behavioral health Ensure providers in your clinic understand how to refer to behavioral health providers Questions? 6
Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)
Protocol Title: Depression & Generalized Anxiety Disorder Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017) Group
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationPsychiatric Consultant Role in Collaborative Care Sept 12, 2013
New York State Collaborative Care Initiative Psychiatric Consultant Role in Collaborative Care Sept 12, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationTreatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationAntidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationPSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust
PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions
More informationPrimary Care Provider & Psychiatric Consultant Roles. PC/PCP Role Session Objectives. Working as a Team. Joseph Cerimele Anna Ratzliff
Primary Care Provider & Psychiatric Consultant Roles Joseph Cerimele Anna Ratzliff PC/PCP Role Session Objectives By the end of the session, participants will: 1. Understand the role of the psychiatric
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationDepression Assessment and Management. John Kern MD Clinical Professor University of Washington
Depression Assessment and Management John Kern MD Clinical Professor University of Washington Handouts Antidepressant Treatment Flowchart Managing antidepressant nonresponse handouts 2 Diagnosis PHQ-9
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More information48 th Annual Meeting. Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5. Disclosure. Depression. Patient Case. Objectives 7/19/2014
48 th Annual Meeting Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Published in 2013 Most published treatment guidelines
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN
UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More information8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation
Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 2 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationStart Low, Go Slow but Treat to Target
Start Low, Go Slow but Treat to Target Pharmacotherapy for Depression, Anxiety and At-Risk Alcohol Use in Late Life September 29, 2014 Audio and Control Panel instruction On the phone? Raise your hand
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationKari A. Stephens, PhD & Wayne Bentham, MD Psychiatry & Behavioral Sciences University of Washington. Approach for doing differential diagnosis of PTSD
IN PRIMARY CARE June 17, 2010 Kari A. Stephens, PhD & Wayne Bentham, MD Psychiatry & Behavioral Sciences University of Washington Defining and assessing Approach for doing differential diagnosis of Best
More informationMedication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015
Medication Management Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015 1 Medication Management Objectives: 1. Principles of psycho-pharmacology
More informationPrimary Mental Health Talk First, Prescribe Later
Primary Mental Health Talk First, Prescribe Later PHARMAC Seminar, Mar 2017 David Codyre, primary care psychiatrist Talk First, Prescribe Later Scenario 1 A 51 yo man presents with a complaint of profound
More informationLife is a miserable thing. I have decided to spend my life thinking about it. Irvin D. Yalom, The Schopenhauer Cure
Life is a miserable thing. I have decided to spend my life thinking about it. Irvin D. Yalom, The Schopenhauer Cure GERIATRIC DEPRESSION Samir Patel, MD Geriatrics and Palliative Medicine and Geriatric
More informationMedications for Borderline Personality Disorder
Medications for Borderline Personality Disorder Sarah Roff MD, PhD Attending Psychiatrist, DBT Unit, Oregon State Hospital Assistant Professor, Public Psychiatry, OHSU sarah.roff@dhsoha.state.or.us Skills
More informationPharmacotherapy of depression
Pharmacotherapy of depression Stuff you already know Stuff you probably know Stuff you possibly don t know Stuff you thought you knew but are mistaken about How long does it take for antidepressants
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More informationUpdates in Therapeutics 2015: Ambulatory Care Pharmacy Preparatory Review and Recertification Course Psychiatric Disorders William A.
Updates in Therapeutics 2015: Ambulatory Care Pharmacy Preparatory Review and Recertification Course Psychiatric Disorders William A. Kehoe, Pharm.D., MA, FCCP, BCPS Professor of Pharmacy Practice University
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationBasics of Benzodiazepine Use Disorder. DATE: March 20, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR
Basics of Benzodiazepine Use Disorder DATE: March 20, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker: Melissa Weimer, DO, MCR, has nothing to disclose. Planning Committee: The members
More informationPharmacological Treatment of Anxiety & Depressive Disorders
Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationThe scope of the problem. Literature review
Past Year: Novartis Ever: Alkermes, Amylin, Behringer- Ingelheim, Biovail, Bristol-Myers Squibb, Eli Lilly, Embryon, GlaxoSmithKline, Merck, Organon, Park-Davis, Pfizer, Sanolfi-Aventis, Smith-Kline Beacham,
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationDisclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017
Psychopharmacology of Pediatric Anxiety and Depression Susan Sharp, DO Clinical Assistant Professor of Child and Adolescent Psychiatry Kansas University Medical Center The Children's Mercy Hospital, 2017
More informationFROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationVolume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 1 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationAnxiety Disorders: First aid and when to refer on
Anxiety Disorders: First aid and when to refer on Presenter: Dr Roger Singh, Consultant Psychiatrist, ABT service, Hillingdon Educational resources from NICE, 2011 NICE clinical guideline 113 What is anxiety?
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationManagement of a HIV-infected patient with a psychiatric disorder
Management of a HIV-infected patient with a psychiatric disorder Maria Ferrara, Modena, Italia Guida Da Ponte, Lisboa, Portugal Jordi Blanch, Barcelona Main complaint Mr M is a 30-year-old HIV+ man In
More informationPanic disorder is a chronic and recurrent illness associated
CLINICAL PRACTICE GUIDELINES Management of Anxiety Disorders. Panic Disorder, With or Without Agoraphobia Epidemiology Panic disorder is a chronic and recurrent illness associated with significant functional
More informationBasics of Benzodiazepine Use Disorder. DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR
Basics of Benzodiazepine Use Disorder DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker disclosure: One time lecture sponsored by Indivior about overlap of pain and opioid
More informationOverview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders
1 Learning Objectives 1. Providers will become familiar with methods of screening for depression and anxiety. 2. Providers will become more comfortable with diagnosis and management of these common pediatric
More informationStrategies for Diagnosing and Treating Depressive Disorders in Primary Care
Strategies for Diagnosing and Treating Depressive Disorders in Primary Care David Katerndahl, MD, MA University of Texas Health Science Center San Antonio, Texas Speaker Disclosure Dr. Katerndahl has disclosed
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAntidepressant tapering advice
Antidepressant tapering advice Professor Tony Kendrick et al, NIHR REDUCE Programme in the UK has kindly made this available to New Zealand prescribers as there is little empirical evidence on how to taper
More informationReviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression
CLINICAL AUDIT Reviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression Valid to November 2022 bpac nz better medicin e Audit Focus This audit helps health professionals
More informationDepression & Suicide 7/11/2017 DISCLOSURES. DSM 5 Depressive Disorders. Objectives
DISCLOSURES Depression & Suicide July 19, 2017 GenaLynne C. Mooneyham, MD, MS Pediatrics/Psychiatry/Child & Adolescent Psychiatry No financial disclosures There may be discussion of off label medication
More informationAntidepressant Treatment of Depression
Antidepressant Treatment of Depression PLEASE REFER TO INTEGRATED CARE PATHWAY FOR INFORMATION RELATING TO THE OVERALL MANAGEMENT OF DEPRESSION SSRI s are first choice agents because they are as effective
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationIntro to Concurrent Disorders
CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,
More informationTreating Pain and Depression
Treating Pain and Depression Without Getting Depressed Joseph P, Arpaia, MD www.jparpaiamd.com More than 50% of patients with chronic pain also have clinically significant depression. Interestingly that
More informationSession 3: Help Me, Doc - I ve Got High Anxiety! Learning Objectives
Session 3: Help Me, Doc - I ve Got High Anxiety! Learning Objectives 1. Recognize the distinguishing features of common anxiety disorders seen in primary care. 2. Use screening measures for diagnosis of
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationAdvances in Diagnosis, Neurobiology, and Treatment of Mood Disorders
Advances in Diagnosis, Neurobiology, and Treatment of Mood Disorders June 13-14, 2016 Field House Coral Gables University of Miami Coral Gables, FL Management of Depression in the Geriatric Patient Samir
More information